Ipamorelin (5mg) Dosage Protocol
Ipamorelin is a selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin. It is considered one of the safest GHRPs.
Add 2.0 mL bacteriostatic water → 2.5 mg/mL (2500 mcg/mL)
200-300 mcg, 2-3 times daily
At 2.5 mg/mL: 8 units = 200 mcg, 12 units = 300 mcg
Lyophilized: -20°C; Reconstituted: 2-8°C for up to 4 weeks
| Week | Daily Dose | Units (per injection) |
|---|---|---|
| Weeks 1-4 | 200 mcg 2x daily | 8 units per dose |
| Weeks 5-8 | 200 mcg 3x daily | 8 units per dose |
| Weeks 9-12 | 300 mcg 2-3x daily | 12 units per dose |
- 1Draw 2.0 mL bacteriostatic water with a sterile syringe
- 2Inject slowly down the vial wall to prevent foaming
- 3Gently swirl until fully dissolved - do not shake
- 4Label with date and concentration, refrigerate immediately
Ipamorelin is a pentapeptide that selectively stimulates growth hormone release through the ghrelin receptor. Unlike other GHRPs, it does not significantly increase cortisol, prolactin, or appetite. Clinical trials (NCT01280344) evaluated its use for post-operative GI recovery.
- Selective GH release without cortisol/prolactin increase
- Supports recovery and sleep quality
- May improve body composition
- Well-tolerated with minimal side effects
- Raun K, et al. Ipamorelin, the first selective GH secretagogue. Eur J Endocrinol. 1998;139(5):552-61
- ClinicalTrials.gov NCT01280344 - Ipamorelin for postoperative ileus
- Prospective study of ipamorelin in bowel resection. Int J Colorectal Dis. 2014
Lyophilized
Store at -20°C, protected from light
Reconstituted
Refrigerate at 2-8°C, use within 4 weeks
Best administered on empty stomach for optimal GH release
- •Research compound - not FDA approved
- •Best combined with GHRH (like CJC-1295) for synergy
- •Fasting enhances GH release response
- •Timing: morning, post-workout, and before bed optimal
Disclaimer: This content is intended for research and educational purposes only. Not intended to diagnose, treat, cure, or prevent any disease. All compounds are for research use only. Dosing information is derived from published scientific literature and clinical studies.